Siglec-15在肿瘤机制中研究进展
Research Progress of Siglec-15 in Tumor Mechanism
DOI: 10.12677/ACM.2023.133652, PDF,    科研立项经费支持
作者: 石洪波, 谭云波, 金礼权*：大理大学第一附属医院普外一科，云南 大理；段耀强：大理大学临床医学院，云南 大理
关键词: Siglec-15；肿瘤；免疫治疗；Siglec-15； Tumor； Immunotherapy
摘要: Siglec-15作为新发现的潜在免疫治疗靶点，其地位与PD-1/PD-L1的地位相当，且Siglec-15在多种肿瘤中都有表达，甚至目前在多种实体瘤中对于PD-1治疗不敏感的情况下，针对Siglec-15涉及的免疫治疗可作为PD-1的补充，可见Siglec-15具有巨大的未来免疫治疗潜力。目前针对Sigle-15的新研究正在不断深入，因此本文章将综合国内外研究，就Sigle-15在肿瘤过程发挥的作用机制进行综述。
Abstract: Siglec-15 as a newly discovered potential immunotherapy target, its status is comparable to that of PD-1/PD-L1, and Siglec-15 is expressed in a variety of tumors, even in a variety of solid tumors that are not sensitive to PD-1 treatment. Immunotherapy designed against Siglec-15 can be used as a supplement to PD-1, indicating that Siglec-15 has great potential for future immunotherapy. At present, the new research on Sigl-15 is deepening. Therefore, this article will summarize the mechanism of Siglec-15 in the process of tumor based on the research at home and abroad.
文章引用：石洪波, 谭云波, 段耀强, 金礼权. Siglec-15在肿瘤机制中研究进展[J]. 临床医学进展, 2023, 13(3): 4545-4550. https://doi.org/10.12677/ACM.2023.133652

参考文献

[1] Sterner, R.C. and Sterner, R.M. (2021) CAR-T Cell Therapy: Current Limitations and Potential Strategies. Blood Cancer Journal, 11, 69. [Google Scholar] [CrossRef] [PubMed]
[2] Angata, T., Tabuchi, Y., Nakamura, K. and Nakamura, M. (2007) Siglec-15: An Immune System Siglec Conserved throughout Vertebrate Evolution. Glycobiology, 17, 838-846. [Google Scholar] [CrossRef] [PubMed]
[3] Klionsky, D.J., Cregg, J.M., Dunn, W.A., et al. (2003) A Unified Nomenclature for Yeast Autophagy-Related Genes. Developmental Cell, 5, 539-545. [Google Scholar] [CrossRef] 
[4] Mizushima, N. (2018) A Brief History of Autophagy from Cell Biology to Physiology and Disease. Nature Cell Biology, 20, 521-527. [Google Scholar] [CrossRef] [PubMed]
[5] Zheng, B., Song, K., Sun, L., et al. (2022) Siglec-15-Induced Autophagy Promotes Invasion and Metastasis of Human Osteosarcoma Cells by Activating the Epithelial-Mesenchymal Transition and Beclin-1/ATG14 Pathway. Cell & Bioscience, 12, 109. [Google Scholar] [CrossRef] [PubMed]
[6] Hou, X., Chen, C., He, X. and Lan, X. (2022) Siglec-15 Silenc-ing Inhibits Cell Proliferation and Promotes Cell Apoptosis by Inhibiting STAT1/STAT3 Signaling in Anaplastic Thy-roid Carcinoma. Disease Markers, 2022, Article ID: 1606404. [Google Scholar] [CrossRef] [PubMed]
[7] Song, K., Ma, J., Gao, Y., et al. (2022) Knocking down Siglec-15 in Osteosarcoma Cells Inhibits Proliferation While Promoting Apoptosis and Pyroptosis by Targeting the Siglec-15/STAT3/Bcl-2 Pathway. Advances in Medical Sciences, 67, 187-195. [Google Scholar] [CrossRef] [PubMed]
[8] Fan, M.K., Zhang, G.C., Chen, W., et al. (2021) Siglec-15 Pro-motes Tumor Progression in Osteosarcoma via DUSP- 1/MAPK Pathway. Frontiers in Oncology, 11, Article ID: 710689. [Google Scholar] [CrossRef] [PubMed]
[9] Yu, Z. and Chen, L. (2016) Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy. JAMA On-cology, 2, 1403. [Google Scholar] [CrossRef] [PubMed]
[10] Guo, H., Yang, J. and Wang, H. (2022) Re-shaping the Tumor Microenvironment: The Versatility of Immunomodulatory Drugs in B-Cell Neoplasms. Frontiers in Immunology, 13, Article ID: 1017990. [Google Scholar] [CrossRef] [PubMed]
[11] Xu, S., Chaudhary, O., Rodríguez-Morales, P., et al. (2021) Uptake of Oxidized Lipids by the Scavenger Receptor CD36 Promotes Lipid Peroxidation and Dysfunction in CD8+ T Cells in Tumors. Immunity, 54, 1561-1577. [Google Scholar] [CrossRef] [PubMed]
[12] Ma, X., Xiao, L., Liu, L., et al. (2021) CD36-Mediated Ferrop-tosis Dampens Intratumoral CD8+ T Cell Effector Function and Impairs Their Antitumor Ability. Cell Metabolism, 33, 1001-1012. [Google Scholar] [CrossRef] [PubMed]
[13] Chen, L. and Han, X. (2015) Anti-PD-1/PD-L1 Ther-apy of Human Cancer: Past, Present, and Future. Journal of Clinical Investigation, 125, 3384. [Google Scholar] [CrossRef] 
[14] Gordon, S. and Martinez, F.O. (2010) Alternative Activation of Macro-phages: Mechanism and Functions. Immunity, 32, 593-60. [Google Scholar] [CrossRef] [PubMed]
[15] Li, H., Zhu, R., Liu, X., et al. (2022) Siglec-15 Regulates the Inflammatory Response and Polarization of Tumor-Associated Macrophages in Pancreatic Cancer by Inhibiting the cGAS-STING Signaling Pathway. Oxidative Medicine and Cellular Longevity, 2022, Article ID: 3341038. [Google Scholar] [CrossRef] [PubMed]
[16] Takamiya, R., Ohtsubo, K., Takamatsu, S., et al. (2013) The Interaction between Siglec-15 and Tumor-Associated sialyl-Tn Antigen Enhances TGF-β Secretion from Monocytes/Macrophages through the DAP12-Syk Pathway. Glycobiology, 23, 178-187. [Google Scholar] [CrossRef] [PubMed]
[17] Wylie, B., Macri, C., Mintern, J.D., et al. (2019) Dendritic Cells and Cancer: From Biology to Therapeutic Intervention. Cancers, 11, 521. [Google Scholar] [CrossRef] [PubMed]
[18] Egen, J.G., Ouyang, W. and Wu, L.C. (2020) Human Anti-Tumor Immunity: Insights from Immunotherapy Clinical Trials. Immunity, 52, 36-54. [Google Scholar] [CrossRef] [PubMed]
[19] Sanmamed, M.F. and Chen, L. (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell, 175, 313-326. [Google Scholar] [CrossRef] [PubMed]
[20] Wang, J., Sun, J., Liu, L.N., et al. (2019) Siglec-15 as an Immune Suppressor and Potential Target for Normalization Cancer Immunotherapy. Nature Medicine, 25, 656-666. [Google Scholar] [CrossRef] [PubMed]

为你推荐